On March 26, 2024, leaders from Ultragenyx shared information about the scientific learnings from its Sanfilippo Syndrome Type A Gene Therapy Program (UX111) to date. Additionally, they spoke about future plans for the Type A gene therapy program and answered questions from the Sanfilippo community.
Cure Sanfilippo Foundation hosted this 90-minute town hall webinar in collaboration with the National MPS Society and Ultragenyx. Chief Scientific Officers Cara O’Neill, MD, of Cure Sanfilippo Foundation and Matthew Ellinwood, DVM, PhD, of the National MPS Society moderated the webinar in conjunction with leaders from Ultragenyx.
To learn more about Sanfilippo Syndrome: curesanfilippofoundation.org/...
#curesanfilippo #sanfilipposyndrome #research #raredisease
28 мар 2024
